CO5271688A1 - Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales - Google Patents

Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales

Info

Publication number
CO5271688A1
CO5271688A1 CO00083607A CO00083607A CO5271688A1 CO 5271688 A1 CO5271688 A1 CO 5271688A1 CO 00083607 A CO00083607 A CO 00083607A CO 00083607 A CO00083607 A CO 00083607A CO 5271688 A1 CO5271688 A1 CO 5271688A1
Authority
CO
Colombia
Prior art keywords
transfer protein
secretion inhibitor
triglyceric
microsomal
apolipoprotein
Prior art date
Application number
CO00083607A
Other languages
English (en)
Inventor
Anne Hickman Maru
Marie Lundy Kristin
Bradley Paul Morgan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5271688A1 publication Critical patent/CO5271688A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El invento se relaciona con métodos y composiciones farmacéuticas útiles en reducir el consumo alimenticio en un animal, preferiblemente un mamífero incluyendo un sujeto humano o un animal de compañía, utilizando un inhibidor de la secreción de la apolipoproteína B/proteína de transferencia de triglicéricos microsomales. El invento preferiblemente se relaciona con métodos y composiciones farmacéuticas útiles en reducir el consumo alimenticio en un animal, preferiblemente un mamífero incluyendo un sujeto humano o un animal de compañía, utilizando un inhibidor de la secreción de la apolipoproteína B/proteína de transferencia de triglicéricos microsomales, y un agente antiobesidad. El invento además proporciona un kit el cual comprende una cantidad de un inhibidor de la secreción de la apolipoproteína B/proteína de transferencia de triglicéricos microsomales y un portador, vehículo o diluyente farmacéuticamente aceptable en una primera forma de dosificación unitaria; una cantidad de un agente anti-obesidad y un portador, vehículo o diluyente farmacéuticamente aceptable en una segunda forma de dosificación unitaria; y un recipiente.
CO00083607A 1999-11-10 2000-11-02 Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales CO5271688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16451399P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
CO5271688A1 true CO5271688A1 (es) 2003-04-30

Family

ID=22594839

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00083607A CO5271688A1 (es) 1999-11-10 2000-11-02 Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales

Country Status (11)

Country Link
EP (1) EP1099438A3 (es)
JP (1) JP2001181209A (es)
KR (1) KR100439384B1 (es)
AU (1) AU777542B2 (es)
CA (1) CA2325282C (es)
CO (1) CO5271688A1 (es)
HU (1) HUP0004454A3 (es)
IL (1) IL139449A0 (es)
NZ (1) NZ508061A (es)
PE (1) PE20010679A1 (es)
ZA (1) ZA200006417B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
AU2005214159A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EP0902785B1 (en) * 1996-04-30 2002-09-04 Pfizer Inc. Processes and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid 2-(2h- 1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-amide
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
SK65499A3 (en) * 1996-11-27 2001-05-10 Pfizer Apo b-secretion/mtp inhibitory amides
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
IL133201A0 (en) * 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)

Also Published As

Publication number Publication date
EP1099438A2 (en) 2001-05-16
KR100439384B1 (ko) 2004-07-09
PE20010679A1 (es) 2001-06-30
NZ508061A (en) 2002-04-26
CA2325282A1 (en) 2001-05-10
CA2325282C (en) 2005-12-06
AU777542B2 (en) 2004-10-21
HU0004454D0 (es) 2001-01-29
HUP0004454A2 (hu) 2001-10-28
KR20010051509A (ko) 2001-06-25
IL139449A0 (en) 2001-11-25
EP1099438A3 (en) 2003-03-19
ZA200006417B (en) 2002-05-08
AU7151900A (en) 2001-05-17
JP2001181209A (ja) 2001-07-03
HUP0004454A3 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
FR14C0080I2 (fr) Methode d'administration d'un anticorps
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
HK1100166A1 (en) Effervescent oral opiate dosage form
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EP1435973A4 (en) SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
AU8867501A (en) Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
MXPA03004499A (es) Kit de repinotan.
JP2004500325A5 (es)
CO5271688A1 (es) Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
CO5261534A1 (es) Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales
SE0001916D0 (sv) Novel formulation
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
BR0005318A (pt) Utilização de inibidores de secreção da apo b/mtp e agentes antiobesidade
AU2001285026A1 (en) Methods and compositions for use in the diagnosis and treatment of chronic immune disease
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner

Legal Events

Date Code Title Description
FC Application refused